New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer . Amsterdam, The Netherlands and Geneva, Switzerland, 19 October 2023 - iOnctura, a ...

Forbius announced that the first patient has been dosed in a Phase 1b trial assessing AVID200 in patients with in patients with myelofibrosis (MF).

Two different approaches to inhibition are being developed, he said: an antibody directed against TGF-1, which is likely to be injectable; and a small molecule directed against the receptor for ...

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications. Feb 24, 2015 3:00am.

AMSTERDAM and GENEVA, Oct. 19, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival ...

Category: Partnering News, R&D News Monday, February 23, 2015 8:00 am EST "This collaboration places our TGF beta receptor kinase inhibitor program into the hands of Bristol-Myers Squibb, a ...